GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, ...

After years of rising obesity rates in the US, the numbers dipped slightly during 2023, though experts disagree about the ...

Ozempic is a drug for diabetes, but it's also being used off-label for weight loss. Its active ingredient has inspired a new ...

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

Results for its new CagriSema drug, while promising, fell below expectations, sending shares of the pharmaceutical giant down ...

Independence Blue Cross said starting Jan. 1 it will only be covering GLP-1 agonists — commonly sold under brand names like ...

An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...

Unless the government intervenes to lower the price or forces insurers to cover the drugs, they will remain out of range for ...

Users on TikTok have touted the benefits of taking berberine supplements, claiming benefits for weight loss, heart health and ...

One lawmaker said the CT Department of Social Services told him the agency wasn’t paying for FDA-approved drugs because of ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Pennsylvania's Medicaid spending per enrollee on Wegovy, Zepbound, and other anti-obesity drugs was third-highest in the ...